Editas Medicine (EDIT) Accumulated Depreciation (2015 - 2023)

Editas Medicine (EDIT) has 9 years of Accumulated Depreciation data on file, last reported at $23.5 million in Q2 2023.

• Quarterly Accumulated Depreciation rose 26.38% year-over-year to $23.5 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $23.5 million (up 26.38% YoY) and the FY2022 annual result came in at $21.5 million, up 38.81% from the prior year.
• Accumulated Depreciation grew to $23.5 million in Q2 2023 per EDIT's latest filing, from $22.0 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $23.5 million in Q2 2023 and bottomed at $5.1 million in Q1 2019.
• The 5-year median for Accumulated Depreciation is $12.6 million (2021), against an average of $13.3 million.
• The widest annual swing landed in 2019, when Accumulated Depreciation climbed 1.0%; it then surged 56.4% in 2020.
• Tracing EDIT's Accumulated Depreciation over 5 years: stood at $7.2 million in 2019, then soared by 54.01% to $11.1 million in 2020, then soared by 39.77% to $15.5 million in 2021, then jumped by 38.81% to $21.5 million in 2022, then rose by 9.13% to $23.5 million in 2023.
• Per Business Quant, the three latest EDIT Accumulated Depreciation figures stand at $23.5 million (Q2 2023), $22.0 million (Q1 2023), and $21.5 million (Q4 2022).

Peer Comparison